National Marrow Donor Program, Minneapolis, Minnesota 55413, USA.
Biol Blood Marrow Transplant. 2010 Feb;16(2):147-56. doi: 10.1016/j.bbmt.2009.08.004. Epub 2009 Sep 30.
Although hematopoietic cell transplantation (HCT) is an effective treatment option for patients with life-threatening blood, immune system, or genetic disorders, many barriers besides a lack of suitably matched donors exist and can have an adverse impact on access and outcomes of HCT. In 2008, the National Marrow Donor Program, through its Office of Patient Advocacy, convened a diverse group of experts and transplantation survivors to identify persistent patient barriers throughout the transplantation process and to make recommendations for programs and initiatives to address these barriers, including new research opportunities. This group included transplantation physicians and other health care providers, relevant subject experts, and representatives from transplantation centers and patient advocacy organizations. Working groups were formed to identify patient barriers to HCT and to recommend and prioritize initiatives as they relate to the pretransplantation period, the early posttransplantation period, long-term survivorship, financial issues, and special populations. This report summarizes the symposium's deliberations and recommendations to address persistent patient barriers throughout the transplantation process.
虽然造血细胞移植(HCT)是治疗危及生命的血液、免疫系统或遗传疾病患者的有效选择,但除了缺乏合适的匹配供体外,还有许多其他障碍会对 HCT 的获得和结果产生不利影响。2008 年,国家骨髓捐赠者计划通过其患者权益办公室召集了一组多元化的专家和移植幸存者,以确定整个移植过程中持续存在的患者障碍,并就解决这些障碍的方案和举措提出建议,包括新的研究机会。该小组包括移植医生和其他医疗保健提供者、相关主题专家以及移植中心和患者权益组织的代表。成立工作组以确定 HCT 的患者障碍,并根据与移植前阶段、移植后早期、长期生存、财务问题和特殊人群相关的障碍,提出并优先考虑举措。本报告总结了专题讨论会审议情况和建议,以解决整个移植过程中持续存在的患者障碍。